|
Jul 23
|
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
|
|
Jun 26
|
Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
|
|
May 14
|
Precigen Reports First Quarter 2024 Financial Results and Business Updates
|
|
May 8
|
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
|
|
Apr 24
|
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
|
|
Apr 24
|
Actym Therapeutics Appoints Thomas Smart as CEO
|
|
Mar 28
|
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
|
|
Mar 20
|
Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Precigen Inc (PGEN) Reports Full Year 2023 Financial Results
|
|
Mar 19
|
Precigen Reports Full Year 2023 Financial Results and Business Updates
|
|
Mar 12
|
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
|
|
Mar 5
|
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
|
|
Jan 16
|
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
|
|
Dec 18
|
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 29
|
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
|
|
Aug 9
|
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
|
|
Aug 9
|
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
|